|
Characteristic
|
Univariate analysis
|
Multivariate analysis
|
|---|
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
|---|
|
Gender
|
0.055
| |
0.07
|
|
Male
|
1 (reference)
| |
1 (reference)
| |
|
Female
|
0.804 (0.644–1.004)
| |
0.812 (0.648-1.017)
| |
|
Age (years)
|
0.567
| |
0.199
|
|
<65
|
1 (reference)
| |
1 (reference)
| |
|
≥65
|
1.070 (0.849–1.347)
| |
0.842 (0.647–1.095)
| |
|
ECOG performance status
|
0.005
| |
<0.001
|
|
<2
|
1 (reference)
| |
1 (reference)
| |
|
≥2
|
1.388 (1.103–1.747)
| |
1.620 (1.244–2.111)
| |
|
Site of primary tumor
|
0.974
| |
0.938
|
|
Colon
|
1 (reference)
| |
1 (reference)
| |
|
Rectum
|
1.004 (0.806–1.250)
| |
1.009 (0.809–1.257)
| |
|
No. of metastatic sites
|
0.002
| |
0.065
|
|
≤2
|
1 (reference)
| |
1 (reference)
| |
|
>2
|
1.417 (1.135–1.769)
| |
1.252 (0.986–1.589)
| |
|
Tumor differentiation
|
<0.001
| |
0.002
|
|
Well or moderate
|
1 (reference)
| |
1 (reference)
| |
|
Poor
|
1.736 (1.385–2.176)
| |
1.484 (1.159–1.901)
| |
|
Pre-chemotherapy ALC (×109/L)
|
0.121
| |
0.391
|
|
<2.70
|
1 (reference)
| |
1 (reference)
| |
|
≥2.70
|
0.841 (0.676–1.047)
| |
0.884 (0.668–1.171)
| |
|
Pre-chemotherapy AMC (×109/L)
|
<0.001
| |
<0.001
|
|
<0.55
|
1 (reference)
| |
1 (reference)
| |
|
≥0.55
|
1.514 (1.204–1.903)
| |
1.703 (1263–2.296)
| |
|
Pre-chemotherapy LMR
|
<0.001
| |
0.004
|
|
<3.11
|
1 (reference)
| |
1 (reference)
| |
|
≥3.11
|
0.568 (0.453–0.712)
| |
0.662 (0.501–0.875)
| |
- Abbreviations as in Tables 1 and 2
